SynthesisNeurosurgical review2025
Efficacy and safety of 5-aminolevulinic acid in meningioma resection: a systematic review and meta-analysis.
Synthesis in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- 5-Aminolevulinic Acid-Based Radiodynamic Therapy for Malignant Gliomas: A Conceptual Framework for Mitochondria-Centered Mechanisms, Target Cell States and Translational Perspectives.Life (Basel, Switzerland) · 2026Review
- Clinical translation of photoacoustic imaging using exogenous molecular contrast agents [Invited].Biomedical optics express · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFluorescence-guided surgery (FGS) using 5-aminolevulinic acid (5-ALA) has gained popularity in managing malignant gliomas by improving tumor boundary visualization, enabling more complete resections, and prolonging progression-free survival (PFS). Recent research has expanded its use to meningiomas, encouraged by its consistent effectiveness in highlighting these tumors. This study aims to evaluate the efficacy and safety of FGS in meningiomas.
methodsWe searched PubMed, Embase, Cochrane, and Web of Science databases following Cochrane and PRISMA guidelines. Eligible studies included those with ≥ 4 patients reporting patients with meningioma who underwent FGS using 5-ALA. Key endpoints included positive fluorescence, fluorescence intensity, Simpson grade, and surgical complications.
resultsData from nine studies, encompassing 361 patients (108 males and 253 females) with a mean age of 59.1 years, were analyzed. A high positive fluorescence rate of 95% (95% CI: 92-98%) was found. Strong fluorescence rate occurred in 81% (95% CI: 65-97%), while weak fluorescence was found in 18% (95% CI: 3-34%). According to the Simpson grading system, 80% (95% CI: 65-95%) achieved grades I and II, while 20% (95% CI: 5-35%) reached grades III and IV. Surgical complications occurred in 10% (95% CI: 2-18%). No complications were directly related to 5-ALA.
conclusionThe study indicates that 5-ALA-guided FGS is safe for meningiomas and improves their Simpson grade, with higher rates of Simpson grades I and II. This underscores the utility of 5-ALA as a valuable tool in the surgical management of meningiomas. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
40619556What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.